LPL and hyperinsulinemic hypoglycemia, familial, 4: Alipopogene Tiparvovec (Glybera), a gene therapy approach for patients suffering from genetic LPL deficiency, was a first attempt to treat the risk of pancreatitis (Fig. 1) [15].